Compare Hafnia Limited Common Shares (HAFN) vs ImmunityBio Inc. Common Stock (IBRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hafnia Limited Common Shares vs ImmunityBio Inc. Common Stock — how do they compare? Hafnia Limited Common Shares trades at $10.13 (market cap $5.67B), while ImmunityBio Inc. Common Stock trades at $10.23 (market cap $10.50B). The key difference: ImmunityBio Inc. Common Stock is the larger of the two by market cap, and Hafnia Limited Common Shares pays a 10.44% dividend while ImmunityBio Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hafnia Limited Common Shares for 0 Days and ImmunityBio Inc. Common Stock for 6 Days on average.
| HAFN | IBRX | |
|---|---|---|
Market Cap | $5.67B | $10.50B |
Volume | 3,240,007 | 30,068,214 |
Sector | Industrials | Health |
52-Week High | $10.92 | $11.55 |
52-Week Low | $5.21 | $1.98 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $6.29B | $10.96B |
Dividend Yield | 10.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HAFN trades at $10.85, down 0.64% on the day, with a neutral technical signal. The company shows strong fundamentals, with a P/E of 8.35 and net income margin of 24.7%. Recent earnings have consistently beaten expectations, and analysts maintain a 100% buy rating. Key developments include a CEO transition and strategic acquisitions.
Outlook is positive due to robust profitability and growth projections, with 2026 revenue expected to reach $2.7B. Risks include market volatility and execution of new strategies. The stock presents a value opportunity with upside potential, supported by strong cash flow and institutional confidence.
ImmunityBio (IBRX) trades at $9.80, down 3.16% on the day, amid a bullish technical setup and strong analyst support. The company reported revenue growth to $166 million in 2026 but remains deeply unprofitable with a net loss of $992 million. Recent FDA approval expansion for ANKTIVA in bladder cancer and high-profile executive appointments signal operational momentum, though cash burn remains a concern with negative operating cash flow.
Outlook is cautiously optimistic given the unanimous buy ratings and regulatory milestones, but investment carries high risk due to persistent losses, heavy reliance on financing, and competitive pressures. The stock's trajectory hinges on successful commercialization and pipeline execution to achieve profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Hafnia Limited Common Shares
Hafnia Limited owns and operates a fleet of product and chemical tankers that transport refined oil products, vegetable oils, and chemicals for oil and chemical companies worldwide, across the Long Range, Medium Range, and Handy tanker segments, headquartered in Singapore.
Read more on HAFN →About ImmunityBio Inc. Common Stock
ImmunityBio develops immune-based therapies for cancer and infectious diseases. Its programs are designed to activate and strengthen the body’s immune response.
Read more on IBRX →
